Pharmacogenetics of Response to GLP1R Agonists

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Sep 27, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Pharmacogenetics of Response to GLP1R Agonists," is studying how different genetic factors affect the way people respond to a medication called semaglutide, which is used for treating obesity and Type 2 diabetes. Researchers are looking for overweight or obese volunteers from the Old Order Amish community in Lancaster County, PA. The goal is to understand how this medication impacts insulin release and how quickly glucose (sugar) leaves the bloodstream. Participants will undergo tests before and after taking semaglutide for six weeks to see these effects.

To be eligible for the trial, individuals should be of Amish descent with a body mass index (BMI) of 27 or higher. However, women who could become pregnant, individuals with a history of diabetes, or those with certain medical conditions cannot participate. If you join the study, you can expect to have your blood tested and monitored closely to see how your body responds to the medication, along with providing DNA samples to help learn more about the genetic factors involved. This research aims to improve treatment options for obesity and Type 2 diabetes by understanding how genetics play a role in medication response.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI greater than or equal to 27 kg/m2
• • Of Amish Descent
• Exclusion Criteria:
• • Woman of childbearing age who is sexually active
• • History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL)
• • Known allergy to semaglutide
• • Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
• • eGFR \< 60 mL/min/1.73 sq. m.
• • Hematocrit \< 35%
• • TSH \< 0.4 o4 \> 5.5
• • AST or ALT in excess of 2X the upper limit of normal
• • Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
• • Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2